BT-20
Referentie 300130
Formaat : 1cryovial
Merk : CLS Cell Lines Service
BT-20 Cells
General information
Description | The BT-20 cell line is a human breast adenocarcinoma cell line that was established in 1958 from the malignant tissue of a 74-year-old Caucasian female patient. This cell line exhibits epithelial-like morphology and is often used in research focused on breast cancer biology, particularly in studies exploring the hormonal regulation of cancer growth, gene expression, and the efficacy of therapeutic agents against breast cancer. BT-20 cells are characterized by their ability to form tumors when implanted in immunocompromised mice, thus serving as a useful in vivo model for breast cancer. These cells express receptors for estrogen, progesterone, and androgen, making them relevant for studies on hormone response pathways. Additionally, genetic analysis of BT-20 cells has revealed mutations in genes such as TP53 and PIK3CA, which are common in breast cancer, supporting their use in genetic and pharmacological research. In vitro, BT-20 cells are used to study the mechanisms of cancer cell proliferation, migration, and invasion. They are also employed to assess the cytotoxicity of chemotherapy agents, making them critical for preclinical testing of anti-cancer drugs. The adaptability of BT-20 cells to various culture conditions and their robust growth in vitro make them a valuable resource for cancer research laboratories focusing on the underlying mechanisms of breast cancer and the development of new therapeutic strategies. |
---|---|
Organism | Human |
Tissue | Breast, mammary gland |
Disease | Invasive ductal carcinoma |
Synonyms | BT 20, BT20 |
Characteristics
Age | 74 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Monolayer, adherent |
Identifiers / Biosafety / Citation
Citation | BT-20 (Cytion catalog number 300130) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Antigen expression | HLA A1, Bw16 (+/-) |
---|---|
Isoenzymes | PGM3, 1, PGM1, 1, ES-D, 1, AK-1, 1-2, G6PD, B, GLO-1, 1-2, Phenotype Frequency Product: 0.0115 |
Oncogenes | wnt4 +, wnt7h + |
Tumorigenic | Yes, in nude mice. Forms grade II adenocarcinomas |
Reverse transcriptase | negative |
Mutational profile | TP53 mut |
Karyotype | modal number = 50, many markers with large subtelocentrics most characteristic. (P87) Hyperdiploid with abnormalities including fragmented chromosomes, breaks, secondary constrictions, translocations, submetacentric and telocentric markers |
Handling
Culture Medium | DMEM:Ham's F12, w: 3.1 g/L Glucose, w: 1.6 mM L-Glutamine, w: 15 mM HEPES, w: 1.0 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:2 to 1:4 is recommended |
Seeding density | 1 x 10^4 cells/cm^2 will yield in a confluent layer in about 6 days |
Fluid renewal | 2 to 3 times per week |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,x CSF1PO: 12 D13S317: 11 D16S539: 11, 14 D5S818: 12 D7S820: 10 TH01: 7, 9, 3 TPOX: 11 vWA: 16, 17 D3S1358: 17 D21S11: 28, 29 D18S51: 17 Penta E: 11, 13 Penta D: 10, 11 D8S1179: 12 FGA: 22, 24 |
HLA alleles | A*: 24:02:01, 24:03:01 B*: 15:01:01, 38:01:01 C*: 03:03:01, 12:03:01 DRB1*: 04:04:01, 13:01:01 DQA1*: 01:03:01, 03:01:01 DQB1*: 03:02:01G, 06:01:01G E: 01:01, 01:03 |